The company unveiled results from the Phase 3 CLL14 trial involving its venetoclax-based therapy for chronic lymphocytic leukemia (CLL).New Venetoclax Data At EHA 2026AbbVie announced new Phase 3 data on a fixed-duration venetoclax-based combination at the EHA 2026 Congress, showcasing the enduring safety and efficacy of the treatment.A final analysis of the Phase 3 CLL14 trial compared venetoclax plus obinutuzumab to chlorambucil plus obinutuzumab in previously untreated patients with CLL and coexisting medical conditions.The data found that venetoclax plus obinutuzumab significantly improved progression-free survival (PFS) compared to chlorambucil plus obinutuzumab.The nine-year analysis demonstrated the long-term off-treatment efficacy and safety of the venetoclax plus obinutuzumab fixed-duration combination, with the median time to next treatment (TTNT) of 7.6 years.After a median follow-up of 9.2 years, treatment with venetoclax plus obinutuzumab showed a median PFS of 6.4 years versus 3.2 years, respectively.How AbbVie Ranks On Value, Growth, Quality And MomentumBelow is the Benzinga Edge scorecard for ABBVIE, highlighting its strengths and weaknesses compared to the broader market: